Madrigal Pharma (MDGL) Tops Q1 EPS by 54c

Madrigal Pharma (NASDAQ: MDGL) reported Q1 EPS of ($3.32), $0.54 better than the analyst estimate of ($3.86). Revenue for the quarter came in at $137.25 million versus the consensus estimate of $112.54 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Evaxion posts $3.7M Q2 loss, advances cancer vaccine pipeline
• Daqo New Energy (DQ) Misses Q2 EPS by 67c